 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C25H23ClN4O4 |
| Molar mass | 478.93 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Pazinaclone (DN-2327) is asedative andanxiolytic drug in thecyclopyrrolone family of drugs. Some other cyclopyrrolone drugs includezopiclone andeszopiclone.
Pazinaclone has a very similar pharmacological profile to thebenzodiazepines including sedative and anxiolytic properties, but with lessamnestic effects,[1] and at low doses it is a relatively selective anxiolytic, with sedative effects only appearing at higher doses.[2]
Pazinaclone produces its sedative and anxiolytic effects by acting as apartial agonist atGABAA benzodiazepine receptors, although pazinaclone is more subtype-selective than most benzodiazepines.[3]
Reaction of 2-amino-7-chloro-1,8-naphthyridine withphthalic anhydride leads to the corresponding phthalimide. Selective reduction of one of the imide carbonyl groups in essence converts that to an aldehyde. Condensation withtert-butyl(triphenylphosphoranylidene)acetate gives the Wittig product.
The carboxylic acid is then treated with diethyl cyanophosphonate to convert that to an activated acid cyanide; reaction with 1,4-dioxa-8-azaspiro[4.5]decane results in formation of the corresponding amide, pazinaclone.
